The promise and potential pitfalls of chimeric antigen receptors. - Wikidata - awgldk - TriplyDB

The promise and potential pitfalls of chimeric antigen receptors.

The promise and potential pitfalls of chimeric antigen receptors.

http://www.wikidata.org/entity/Q34970378

about

Focus on adoptive T cell transfer trials in melanoma Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Synthetic conversion of a graded receptor signal into a tunable, reversible switch Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Genetic instability in the tumor microenvironment: a new look at an old neighbor CARs in chronic lymphocytic leukemia -- ready to drive A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19 Developing strategies in the immunotherapy of leukemias Primer on tumor immunology and cancer immunotherapy Novel immunotherapies for hematologic malignancies Clinical application of adoptive T cell therapy in solid tumors Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review One-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism.Identification of Amino Acids that Account for Long-Range Interactions in Two Triosephosphate Isomerases from Pathogenic Trypanosomes CAR therapy: the CD19 paradigm B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Immune-based therapeutics for pediatric cancer.FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance Strategies to genetically engineer T cells for cancer immunotherapy.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Biology and clinical application of CAR T cells for B cell malignancies Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.The basic principles of chimeric antigen receptor design.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.Immunotherapy of human cancers using gene modified T lymphocytes.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

P2860

Q21328679-972AEB74-3C71-4E00-BC6E-444468DD2FB6 Q24594920-9E748C23-843A-439B-93AF-0ED0A71C296F Q24632975-42C5FEC6-5DE3-4925-85C1-1A6C9D0A602C Q24634044-B645AEFF-1E3E-46BE-A366-B5CEBA0645F8 Q26741260-A343432B-F2EF-40DD-BFE5-7A31224ADC8F Q26753082-6090CD60-D1E6-48CD-9431-30CAAA505FE7 Q26795540-2182E690-4358-442B-865B-A1D607B05D2B Q26801374-CF796F87-788F-47D2-8732-5779C6436238 Q26830526-F4218F10-7C69-46A1-8429-F823080FFD43 Q26849476-71D7CD38-0AE4-47A6-B2EB-589F234AA37B Q26996310-AB39B06D-D6A3-4B8F-AF25-D31D4C07DB50 Q27001126-17481C96-65D8-43A5-8AEF-8FD9079CD6E9 Q27004436-BE22D59D-B55A-4FFF-A974-5DBC0BEDAEC5 Q27011283-A89F585C-C67B-4F70-B3F4-015E8EB0C18B Q27027243-28A22BF4-E9A2-4CB4-BA44-A0FBED3EABD5 Q27304386-A543A94E-CED9-414E-8836-3F76F39F02F8 Q27339549-52C00BA2-3558-4A8D-8BAF-C2E33BC35B4E Q27667637-3AEE31AD-0939-4A33-B361-B3DCAE352582 Q28081642-D0F20021-5E03-45B5-BC71-C2FC1F7E2D35 Q29620717-75C74063-31D1-460B-A812-BC4A55A78597 Q29622949-CB233989-1FAC-47F4-B42E-AC6ED267F85F Q30600094-FE98631F-0A50-48E4-B632-894B7DB9F38F Q33530527-C66C0574-4067-48D7-B820-F191CACF2F0B Q33604121-6846A253-3715-4034-9685-2188799333CA Q33607015-9E681310-0911-40FA-9FA2-568DB321836D Q33655849-ABEE2176-3471-4ACD-AB73-ACED4610DAD4 Q33752982-87B2F0C1-A519-4D6E-A2C1-3CA91CD32916 Q33907565-7A565662-DCC2-4F60-B2C1-6C00D7D34D5B Q33960119-C80EAB33-0579-4680-A819-99A8C05C57DB Q34007762-F12E9FBA-EA1B-4B9C-A4ED-399B95EC7001 Q34036213-BB4233F4-66B2-43D2-8807-403DC33FC439 Q34042430-2F26AAB5-0B58-4210-94D9-13FF6A3AF459 Q34046041-BA53606C-0D08-45AF-804D-33D61B705228 Q34046489-C2892082-E836-4B46-9CB5-387F348AC81E Q34055865-61FE9CC3-E6C3-40E1-870D-8921E7843B85 Q34122292-D60BA3C8-F88F-493D-8724-F814A4578C09 Q34153598-3DEE27ED-918B-4AED-8B02-37385C5B36D8 Q34166288-5309DC72-0447-421B-938F-C85A4E86343E Q34188383-17DCBE61-ADDA-4003-819E-1A0C40690C82 Q34310912-9682574E-3495-43B8-B829-354DD91B1F2E

P2860

The promise and potential pitfalls of chimeric antigen receptors.

http://www.wikidata.org/entity/Q34970378

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

The promise and potential pitfalls of chimeric antigen receptors.

@ast

The promise and potential pitfalls of chimeric antigen receptors.

@en

The promise and potential pitfalls of chimeric antigen receptors.

@nl

type

label

The promise and potential pitfalls of chimeric antigen receptors.

@ast

The promise and potential pitfalls of chimeric antigen receptors.

@en

The promise and potential pitfalls of chimeric antigen receptors.

@nl

prefLabel

The promise and potential pitfalls of chimeric antigen receptors.

@ast

The promise and potential pitfalls of chimeric antigen receptors.

@en

The promise and potential pitfalls of chimeric antigen receptors.

@nl

P1433

Q34970378-2B839C51-4283-47D5-8DE1-B0F490A98A1B

P1476

Q34970378-D4CBE6FD-DA01-446C-83F4-F881ADD0B2EE

P2093

Q34970378-6D374FF8-2A5E-431A-A958-DFE3D4E6A6CF

Q34970378-CF8F2CB0-C9FF-4F20-B977-909900D79F22

Q34970378-F8DD5F7D-1A65-4955-BC62-8250B7380B2B

P2860

Q34970378-04A05A0D-4101-496E-8F5E-05E9DF69DED5

Q34970378-0CFEF68A-CFEB-4E9C-87D7-F6F1187461A0

Q34970378-0D9214CB-1A3A-4D79-9E03-483EB49D85ED

Q34970378-0F39C0BE-8EFF-4D6F-9654-C115CE827C10

Q34970378-12C26D34-0D8D-46A1-9754-0885E002468E

Q34970378-17FE0191-0E22-43CC-9296-1325B2788DFC

Q34970378-1A3CC281-C997-4111-B11D-6586140285EB

Q34970378-1A5AE956-6609-4ECA-9E4E-F013EB8D32B3

Q34970378-1BADD185-46B5-4FFF-A64B-C239AAF506C1

Q34970378-1BFE8944-6136-4B40-A1D0-A1AF188E5105

P304

Q34970378-621A159E-9BD9-41CA-92F9-A1A7E63EB272

P31

Q34970378-D9A47F15-C6E2-4A12-A939-9BCBAB9F18BD

P356

Q34970378-92F267B8-82E9-450B-B51A-71FF42D7CC5C

P433

Q34970378-C186BAD9-508A-4521-8B15-725E2CE4FBE9

P478

Q34970378-E4E57D82-D19F-4CAC-9F76-403D20B171E7

P577

Q34970378-CED737F9-EADF-4BBA-B22E-6F4F01EB66D8

P5875

Q34970378-FB720577-F280-4719-A80A-590CF16CD22E

P698

Q34970378-6DCA3E92-C633-412F-91EC-28D193066FE3

P932

Q34970378-4324E797-51B3-4D43-A020-EA50180EA02D

P356

J.COI.2009.02.009

P1433

Current Opinion in Immunology

P1476

The promise and potential pitfalls of chimeric antigen receptors.

@en

P2093

Isabelle Rivière

http://www.w3.org/2001/XMLSchema#string

Michel Sadelain

http://www.w3.org/2001/XMLSchema#string

Renier Brentjens

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.

Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production.

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

Display, engineering, and applications of antigen-specific T cell receptors.

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.

P304

215-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COI.2009.02.009

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24240493

http://www.w3.org/2001/XMLSchema#string

P698

19327974

http://www.w3.org/2001/XMLSchema#string

P932

5548385

http://www.w3.org/2001/XMLSchema#string